

ENANTA PHARMACEUTICALS INC  
Form 8-K  
February 25, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**  
**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 19, 2015**

**ENANTA PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-35839**  
**(Commission File**  
  
**Number)**

**04-3205099**  
**(IRS Employer**  
  
**Identification No.)**

**500 Arsenal Street, Watertown, Massachusetts 02472**

**(Address of principal executive offices and zip code)**

**(617) 607-0800**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

At the Annual Meeting held on February 19, 2015, Enanta's stockholders voted on the following proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 15, 2015.

**Proposal No. 1: To Elect Two Class II Directors to Serve until the 2018 Annual Meeting.** The stockholders re-elected the following individuals as Class II directors of the Company:

|                                 |                  |                       | <b>Broker</b>    |
|---------------------------------|------------------|-----------------------|------------------|
| <b>Name of Director Nominee</b> | <b>Votes For</b> | <b>Votes Withheld</b> | <b>Non-Votes</b> |
| George S. Golumbeski            | 10,917,043       | 61,760                | 2,932,094        |
| Terry C. Vance                  | 10,543,849       | 434,954               | 2,932,094        |

**Proposal No. 2: To Ratify the Appointment of Enanta's Independent Registered Public Accounting Firm.** The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2015.

|                  |                      |                | <b>Broker</b>    |
|------------------|----------------------|----------------|------------------|
| <b>Votes For</b> | <b>Votes Against</b> | <b>Abstain</b> | <b>Non-Votes</b> |
| 13,722,667       | 30,182               | 158,048        | 0                |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ENANTA PHARMACEUTICALS, INC.**

Date: February 25, 2015

By: /s/ Paul J. Mellett  
Paul J. Mellett

Senior Vice President, Finance and Administration  
and Chief Financial Officer